Advertisement

Topics

Gilead to pay $12 Billion for Kite Pharma

04:40 EDT 4 Sep 2017 | CHEManager

US drugmaker Gilead Sciences has agreed to pay almost $12 billion to acquire compatriot Kite Pharma.  Through the cash transaction, it will gain access to Car-T, Kite’s cutting-edge chimeric antigen therapy treatment for cancer. Both companies are based in California.

Original Article: Gilead to pay $12 Billion for Kite Pharma

NEXT ARTICLE

More From BioPortfolio on "Gilead to pay $12 Billion for Kite Pharma"

Quick Search
Advertisement
 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...